ANS Fall 2022 Scientific Program
“Super Saturday” - September 10, 2022
Philadelphia, PA
Marriott Grand Ballroom Salon F

12:45 PM - 1:00 PM - ANS BUSINESS MEETING

ANS SCIENTIFIC SESSION

1:00 PM - WELCOME AND OPENING REMARKS
Fred F. Telischi, MD - ANS President

1:05 PM – 2:05 PM
PANEL - "COCHLEAR GENE THERAPY: FROM BENCH TO BEDSIDE"
Lawrence R. Lustig, MD – Moderator
Ronna Hertzano, MD, PhD – “Molecular Genetic Mechanisms of Hearing Loss”
Wade Chien, MD – “Mouse Models of Genetic Deafness”
Elliot Shearer, MD, PhD – “Genetic Testing in Humans”
Jennifer Wellman – “Translating Gene Therapy to Humans”

2:07 PM – 2:52 PM – FRANKLIN M. RIZER MEMORIAL LECTURE
“SINGLE-SIDED DEAFNESS: ON THE PATH TO BINAURAL HEARING”
Hillary A. Snapp, AuD, PhD
Chief of Audiology, Associate Professor
University of Miami Miller School of Medicine

2:53 PM – 3:15 PM - MIDDAY BREAK

3:17 PM – 4:17 PM
PANEL – “DIAGNOSIS AND MANAGEMENT OF SKULL BASE OSTEOMYELITIS”
Ana H. Kim, MD and Brian P. Perry, MD – Co-Moderators
Michal Kaufman-Yehezkeli, MD
Paul W. Gidley, MD
Suyash Mohan, MD
Valerianna K. Amorosa, MD
Katherine Belden, MD

4:20 PM – 5:20 PM
PANEL - ACQUIRED CHOLESTEATOMA: OLD FOE, NEW APPROACHES
Simon I. Angeli, MD – Moderator - “Introduction on Current Accepted Definitions, Staging and Prognosis”
Sarah Mowry, MD - “Canal Wall Up and Canal Wall Reconstruction Techniques”
John Dornhoffer, MD - “Nuances of Pediatric Cholesteatoma”
Daniel Jethanamest, MD - “Endoscopic Approach to Cholesteatoma, When It Is Indicated, When It Is Not”
Jennifer Alyono, MD, MS - “Difficult Mastoid Cavity, How to Manage It, How to Prevent It”

5:22 – 5:30 PM – CLOSING REMARKS/ADJOURN
Fred F. Telischi, MD - ANS President
1. Continuing Medical Education Credit Information

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Surgeons and American Neurotology Society. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™
The American College of Surgeons designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

2. Program Objectives

What are the practice or patient care problems being addressed by this activity?

Overall this activity addresses gaps in knowledge and practice that reflect evolving understanding and perspectives in the diagnosis and management of health conditions of the ear and skull base. The Study Groups provide a platform for shared learning through the presentation and open discussion of complex and rare cases. These sessions highlight the core principles of standard practice while challenging commonly held assumptions that create opportunities for further clarification or research. The scope of the gaps addressed by the following activities are indicated:

Vestibular Disorders Study Group – Heterogeneous clinical presentations of vestibular disorders, and risks and benefits of evolving management options

Facial Nerve Study Group – Risk benefit assessment of various strategies (and timing) to address acquired disorders of the facial nerve in children and adults.

Vestibular Schwannoma Study Group – Long-term functional and tumor control outcomes, which influence candidacy and patient counseling regarding appropriate expectations.

William House Cochlear Implant Study Group – With broadening candidacy criteria, cochlear implant has become a viable option for management hearing loss in newer disease categories such single side deafness associated with acoustic neuroma removal. A growing experience by presenting clinicians will provide early and preliminary experience and results in similar new and complex clinical scenarios.

Panel on Gene Therapy in Otology/Neurotology: This activity will help us to better understand what the future holds for gene therapy in the field of Otology/Neurotology.
Panel on Malignant Otitis Externa: This activity will address controversies in the contemporary management of malignant otitis externa.

Panel on Cholesteatoma: This activity will be addressing the contemporary management of acquired cholesteatoma, including solutions to minimize chance of disease recurrence, maximize functional outcomes, and prevent complications.

How will this activity improve the learners' competence (knowledge in action), performance (skill set) and/or patient outcomes (impact of care)?

Competence: The educational program is designed to address the topics identified as practice gaps through individual presentations and in-depth panel discussions. The study groups will emphasize case-based learning and opportunity to demonstrate the application of core principles and new information to clinical decision making.

Performance: All activities will review established knowledge, present areas of controversy and define skills that require additional development within our field or in consultation with other disciplines. Means by which these skills can be acquired or improved will also be presented.

Patient Outcomes: The impact of clinical decision making, professionalism and health system structures on clinical outcomes will be presented and discussed with assistance of the moderators. Improvement in recognizing, diagnosing, and managing disorders of the inner ear.

State the learning objectives for this activity (number can vary). Learning objectives begin with a verb and should complete this statement: "At the conclusion of this activity, the learner should be able to..."

1. To evaluate and manage vestibular disorders based on a better understanding of the differential diagnosis and potential consequences of various treatment options
2. To discuss and demonstrate core principles of facial nerve management in a variety of conditions that arise in pediatric and adult populations
3. To illustrate and discuss through case presentations the range of indications, benefits and risks of microsurgery and radiosurgery in acoustic neuroma cases
4. To demonstrate and discuss the implementation of expanded CI candidacy in the clinical management of sensorineural hearing loss
5. To draw from a broader clinical experience and the latest research when managing patients who present with malignant otitis externa.
6. To identify and apply evolving gene therapy technologies to the practice of otology and neurotology.
7. To evaluate and manage cholesteatomas, including intra- and postoperative decision-making.

3. Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any ineligible company held in the last 24 months. Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Please see the full disclosure list as a link on the website program page and onsite at the meeting.
4. Commercial Support Acknowledgement

The American Neurotology Society wishes to recognize and thank the following companies for their monetary commercial support:

In alphabetical order

ADVANCED BIONICS
COCHLEAR AMERICAS
MED-EL
OTICON MEDICAL